Although New Jersey’s biopharmaceutical sector opposed H.R. 3, we share its overriding goal – to ensure that patients can access the treatments and cures that these companies work so hard to discover. While many provisions in H.R. 3 wouldn’t actually lower costs for patients, we will continue seeking comprehensive, realistic ways to lower costs for patients while ensuring that new medical breakthroughs can continue to be discovered. Several pragmatic proposals to achieve this are worthy of close consideration… Please read more here.
Menu